BMY · Bristol Myers Squibb Co
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Growth Portfolio revenues | $7.56B | FY2026 Q2 | +14.6% |
|
|
|||
| Legacy Portfolio revenues | $5.42B | FY2026 Q2 | -4.4% |
|
|
|||
| Total Growth Portfolio | $7.56B | FY2026 Q2 | +14.6% |
|
|
|||
| Total Legacy Portfolio | $5.42B | FY2026 Q2 | -4.4% |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BMY
this stock
Bristol Myers Squibb Co
|
$130.39B | +18.3% | -0.2% | 14.0 | 2.6% |
|
LLY
ELI LILLY & Co
|
$1.11T | +9.8% | +44.7% | 39.6 | 1.0% |
|
JNJ
Johnson & Johnson
|
$627.42B | +25.8% | +6.0% | 30.2 | 1.1% |
|
ABBV
AbbVie Inc.
|
$442.24B | +9.2% | +8.6% | 70.7 | 1.3% |
|
MRK
Merck & Co., Inc.
|
$335.14B | +29.1% | +1.3% | 108.7 | 1.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BMY | -1.4% | +5.1% | +4.2% | -2.3% | +18.3% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -1.8% | +0.6% | -9.6% | -6.2% | +4.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.